The Food and Drug Administration (FDA) has granted approval to drug maker Coviden for a generic version of the painkiller Actiq (fentanyl citrate), made by Cephalon. Coviden plans to start selling six different doses of the drug, a powerful painkiller prescribed to cancer patients who have become tolerant to opioids. Barr Pharmaceuticals also makes a generic version of Actiq.

Actiq is given as a lollipop lozenge, a method of delivery more easily tolerated by cancer patients. While the FDA-approved use of fentanyl citrate is strictly limited to cancer patients already under pain management, the drug’s off-label use for the treatment of headaches and backaches has become alarmingly popular. Fentanyl citrate is a powerful painkiller. No dosage is safe for patients who have not already become tolerant to opioids, and as a result, it has been linked to fatal respiratory complications. To date, 127 deaths and 91 incidents of severe side effects have been associated with use of Actiq.

Cephalon’s Fentora, a similar but much more powerful version of Actiq, was also found to have an off-label use of as much as 90 percent.

Doctors have the authority to prescribe prescription drugs for “off-label” use; however, drug companies are not allowed to promote uses that are not approved by the FDA. After a study identified the high off-label use of Actiq and Fentora, the FDA’s Office of Criminal Investigations and the U.S. Attorney General launched an investigation into Cephalon’s marketing practices.  That investigation is ongoing.

Source: Associated Press



We're here to help!

We live by our creed of “helping those who need it most” and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked * may be required for submission.


Best for clients

Great firm. Supports the community. They want what is best for their clients.

—Jennifer